J. Lauring

发表

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer

Doron Lipson, Gary L Rosner, Christopher D Gocke, 2016, Clinical Cancer Research.

Knockin of mutant PIK3CA activates multiple oncogenic pathways

B. Park, K. Bachman, H. Konishi, 2009, Proceedings of the National Academy of Sciences.

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells

Hiroyuki Konishi, David Cosgrove, Yuko Konishi, 2011, Proceedings of the National Academy of Sciences.

A PCR-based high-throughput screen with multiround sample pooling: application to somatic cell gene targeting

B. Park, H. Konishi, B. Karakas, 2007, Nature Protocols.

TORn in Two Over Breast Cancer Drug Resistance.

B. Park, J. Lauring, 2013, Oncology.

Engineering targeted chromosomal amplifications in human breast epithelial cells

S. Springer, A. Price, J. Lauring, 2015, Breast Cancer Research and Treatment.

A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.

B. Park, D. Laheru, J. Axilbund, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA.

B. Park, P. Hurley, J. Beaver, 2015, Clinical biochemistry.

The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation

A. Weeraratna, P. Argani, A. D. De Marzo, 2012, Breast Cancer Research.

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation

Melissa L. Johnson, E. Haura, P. Cassier, 2022, The oncologist.

NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

B. Garcia, Wei Li, Y. Xi, 2011, Molecular cell.

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation

P. Argani, J. Hicks, A. D. De Marzo, 2016, Oncotarget.

HER2 missense mutations have distinct effects on oncogenic signaling and migration

R. Bose, A. Cimino-Mathews, K. Konstantopoulos, 2015, Proceedings of the National Academy of Sciences.

Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes

B. Park, A. Meeker, C. Heaphy, 2015, Oncotarget.

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.

A. Wolff, B. Park, J. Lauring, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells

B. Park, H. Konishi, M. Mohseni, 2011, Cancer biology & therapy.

GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers

R. Scharpf, D. Rosen, J. Lauring, 2017, Oncotarget.

TMSB 4 Y is a Candidate Tumor Suppressor on the Y Chromosome and is Deleted in Male Breast Cancer

P. Argani, B. Park, A. Meeker, 2016 .

TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer

P. Argani, B. Park, A. Meeker, 2015, Oncotarget.

Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.

B. Park, K. Bachman, H. Konishi, 2007, Cancer research.

Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations

B. Vogelstein, K. Polyak, D. Gorkin, 2010, Oncogene.

Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine

Anandita Rajpurohit, Josh Lauring, J. Lauring, 2012, Oncotarget.

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

R. Arceci, B. Park, H. Konishi, 2008, Blood.

Active growth signalling promotes cancer cell sensitivity to the CDK7 inhibitor ICEC0942

M. Tyers, J. Coulombe-Huntington, G. Sava, 2021, bioRxiv.

c-Myb Binds to a Sequence in the Proximal Region of the RAG-2 Promoter and Is Essential for Promoter Activity in T-Lineage Cells

M. Schlissel, J. Lauring, Qian-fei Wang, 2000, Molecular and Cellular Biology.

Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.

Dhanashree S. Kelkar, A. Pandey, A. Madugundu, 2019, The Journal of clinical investigation.

Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer

Antonio C. Wolff, Leslie Cope, Vered Stearns, 2014, Clinical Cancer Research.

Distinct Factors Regulate the MurineRAG-2 Promoter in B- and T-Cell Lines

M. Schlissel, J. Lauring, Mark Schlissel, 1999, Molecular and Cellular Biology.

Promoter in Band T-Cell Lines RAG-2 Distinct Factors Regulate the Murine

M. Schlissel, J. Lauring, 1999 .

A conserved transcriptional enhancer regulates RAG gene expression in developing B cells.

M. Schlissel, Y. Zhuang, D. Cado, 2003, Immunity.

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.

Hyunseok Kang, Christopher D Gocke, David M Loeb, 2017, JCO precision oncology.

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.

A. Wolff, B. Park, V. Stearns, 2021, Clinical breast cancer.

MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers

R. Scharpf, P. Argani, A. Cimino-Mathews, 2014, Proceedings of the National Academy of Sciences.

Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

R. Gray, K. Flaherty, L. Rubinstein, 2022, JCO precision oncology.

Molecular Cell NSD 2 Links H 3 K 36 me 2 to Myeloma Pathogenesis lysine methyltransferase , SETD

B. Garcia, Y. Xi, B. Park, 2011 .

NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability

R. Scharpf, B. Park, M. Mohseni, 2015, Proceedings of the National Academy of Sciences.

Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma.

C. Lin, T. Karantanos, Y. Kang, 2018, The oncologist.

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Daniel F. Hayes, Arul M. Chinnaiyan, Heather A. Parsons, 2015, Clinical Cancer Research.

PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System

Anandita Rajpurohit, D. Rosen, J. Beaver, 2013, Clinical Cancer Research.

Tamoxifen-stimulated growth of breast cancer due to p21 loss

P. Argani, A. D. De Marzo, B. Park, 2008, Proceedings of the National Academy of Sciences.

The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation

A. Weeraratna, P. Argani, A. D. De Marzo, 2012, Breast Cancer Research.

Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity

J. Lauring, K. H. Yi, 2015, Oncotarget.

Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.

P. Argani, B. Park, H. Konishi, 2013, Cancer research.

Molecular and Cellular Pathobiology Single Copies of Mutant KRAS and Mutant PIK 3 CA Cooperate in Immortalized Human Epithelial Cells to Induce Tumor Formation

P. Argani, B. Park, H. Konishi, 2013 .

ESR 1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Daniel F. Hayes, Arul M. Chinnaiyan, Heather Parsons, 2015 .

Laboratory and Clinical Implications of Incidental and Secondary Germline Findings During Tumor Testing.

Marilyn M. Li, Brad W Jensen, J. Myles, 2021, Archives of pathology & laboratory medicine.

PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity

B. Park, D. Rosen, P. Hurley, 2017, Breast Cancer Research and Treatment.

Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer.

A. Wolff, J. Lauring, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study.

Ó. Rodríguez Faba, R. Meijer, N. Shore, 2023, Journal of Clinical Oncology.

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

A. Brunner, U. Germing, I. Avivi, 2021, Blood.

Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.

David J. Sims, K. Flaherty, L. Rubinstein, 2018 .

Using cancer genomics to guide clinical decisions

M. Burkard, D. Deming, J. Lauring, 2017, Cancer.

BEAMing Sheds Light on Drug Resistance

B. Park, J. Lauring, 2011, Clinical Cancer Research.

TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer

P. Argani, B. Park, A. Meeker, 2015, Oncotarget.

PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System

D. Rosen, J. Beaver, J. Lauring, 2013, Clinical Cancer Research.

Pik3ca and Akt1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System Running Title: Pik3ca and Akt1 Mutant Cells Differ in Drug Sensitivity

J. Beaver, J. Lauring, J. Gustin, 2022 .